The Gray Lady Weighs in on Ozempic

Today the New York Times ran a few letters-to-the-editor on it's op-ed on Ozempic and the costs and benefits of GLP-1 agonists. Mine didn't make the cut this time -- but here it is for your consideration:
Source: drugwonks.com Blog - Category: Pharmaceuticals Source Type: blogs